| Zuhua Chen,Lin Shen. Advantages and limitations in the establishment and utilization of patient-derived xenografts in gastric cancer. Oncol Transl Med, 2017, 3: 3-9. |
| Advantages and limitations in the establishment and utilization of patient-derived xenografts in gastric cancer |
| Received:August 26, 2016 Revised:January 22, 2017 |
| View Full Text View/Add Comment Download reader |
| KeyWord:patient-derived tumor xenograft (PDTX); gastric cancer (GC); preclinical research |
| Author Name | Affiliation | E-mail | | Zuhua Chen | Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China | 1411110423@bjmu.edu.cn | | Lin Shen | Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Beijing 100142, China | lin100@medmail.com.cn |
|
| Hits: 8909 |
| Download times: 10035 |
| Abstract: |
| Owing to the high genetic heterogeneity of tumors, small number of therapeutic strategies available, and
frequent presentation of drug resistance, the prognosis for patients with advanced gastric cancer (AGC)
are unsatisfactory. The utility of traditional cancer cell lines in translational research is limited by their poor
correspondence to the genomic alterations and expression profiles that occur in actual patient tumors. In
the last decade, increasing attention has been given to patient-derived tumor xenografts (PDTXs), which
can faithfully recapitulate the histopathology, molecular characteristics, and therapeutic responses of the
patient’s tumor. However, the widespread development and utilization of PDTXs is restricted by factors
such as the timeframe of establishment, lymphoma transformation during passaging, the immunodeficient
microenvironment, and pharmacokinetic differences between mice and humans. In this review, we
summarize the establishment and characterization of PDTX models for gastric cancer (GC). We then
weigh the advantages and limitations of PDTXs when used to evaluate novel compounds, identify effective
biomarkers, demonstrate resistance mechanisms, and predict clinical outcomes. |
| Close |
|
|
|